Last updated: February 15, 2026
Overview of NDC 00002-3238
NDC 00002-3238 identifies Lipitor (atorvastatin calcium), a statin medication used for lowering cholesterol and preventing cardiovascular disease. Lipitor—originally developed by Pfizer—was launched in 1997 and became one of the top-selling drugs globally. Its patent expired in the United States in November 2011, leading to widespread generic availability.
Market Landscape
Historical Sales and Market Penetration
- Peak Sales Period: 2004-2010, with annual revenues exceeding $12 billion (Pfizer annual reports).
- Post-Patent Launch Impact: Generic versions entered the U.S. market rapidly after patent expiry, causing sales to decline sharply.
- Current Market Share: As of 2022, branded Lipitor accounts for approximately 5-10% of statin prescriptions; generics command over 85% of the market share in the U.S. (IQVIA).
Current Commercial Status
- Form: Tablet
- Strengths: 10 mg, 20 mg, 40 mg, 80 mg
- Key Competitors: Simvastatin, rosuvastatin, pravastatin, ceramic statins, biosimilars
Regulatory Status and Patent Information
- Original Patent Expiry: November 2011
- Patent Litigation: Several patent challenges delayed the entry of certain formulations, but now only generics are authorized.
- FDA Approvals: Multiple generic manufacturers have FDA approval for atorvastatin tablets.
Market Size and Forecast
| Year |
Global Statin Market (USD billion) |
Lipitor Market Share |
Estimated Lipitor Revenue (USD billion) |
| 2022 |
16.4 |
8-10% |
0.8 - 1.6 |
| 2025 |
17.5 |
5-8% |
0.9 - 1.4 |
| 2030 |
19.2 |
3-5% |
0.6 - 0.9 |
Sources: IQVIA, Forte Research, market analysis reports (2022–2023).
Price Projection
Historical Pricing Trends
- Branded Lipitor (Pre-2011): Approximately $3.50-$4.50 per pill (for a 20 mg dose).
- Post-Patent Expiry: Generic atorvastatin prices fell below $0.20 per pill, with significant discounts offered by multiple manufacturers in the U.S.
Current Pricing
- Brand (Lipitor): Approx. $350 for a 30-day supply of 20 mg tablets (retail prices vary).
- Generic: US prices range between $10 and $30 monthly, depending on pharmacy and dosage.
Future Price Trends
- Generic Stability: Prices may stabilize around $8-$15 per month by 2025 with increased competition.
- Potential Premiums: If a new formulation, delivery system, or combination therapy is introduced, prices could rise if approved.
Influencing Factors on Pricing and Market Share
- Patent Litigation and Exclusivity: Patent disputes can temporarily restrict generic entry and sustain higher prices.
- Regulatory Approvals: Any new FDA approvals—such as combination pills—may influence market dynamics.
- Insurance and Reimbursement: Payers favor generics, pushing branded prices downward.
- Supply Chain: Manufacturing capacity and supply chain stability affect pricing levels.
Strategic Outlook
- Generic Dominance: Existing generics dominate the market, limiting margins for branded Lipitor.
- Biosimilar and Alternative Therapies: Increasing competition from biosimilars and novel lipid-lowering agents like PCSK9 inhibitors restrict Lipitor’s market share.
- Lifecycle Management: Pfizer's exit from Lipitor production has been finalized; any new formulations or delivery methods would be experimental or niche.
Conclusion
The market for atorvastatin under NDC 00002-3238 has transitioned to highly genericized, low-price competition. Sales are expected to decline as newer therapies take market share, unless repositioned through combination therapies or new formulations. Pricing for generic atorvastatin is projected to stabilize between $8 and $15 per month in the coming years, with potential for marginal variation based on market dynamics.
Key Takeaways
- Lipitor’s global market share has decreased significantly since patent expiry, with generics dominating.
- Sales revenues are forecasted to stabilize below $1.5 billion annually by 2025.
- Prices for generic atorvastatin are expected to hover around $8–$15 per month.
- Market entry of new lipid-lowering therapies may further diminish Lipitor’s role.
- Patent litigation delays historically influenced pricing, but now generics face minimal IP barriers.
FAQs
Q1: Will Lipitor regain market share with new formulations?
It is unlikely. Reintegration depends on regulatory approval and market acceptance. Current trends favor low-cost generics and new classes of lipid-lowering drugs.
Q2: How do biosimilars or new competitors affect Lipitor prices?
Biosimilars and new therapies, such as PCSK9 inhibitors, diminish Lipitor’s market share and exert downward pressure on prices of existing atorvastatin products.
Q3: Are there patent protections remaining for Lipitor?
No. Pfizer’s patent expired in 2011; subsequent patent challenges have not resulted in extended exclusivity.
Q4: What is the primary driver of atorvastatin’s market decline?
Generic competition and the availability of alternative therapies with improved efficacy or convenience.
Q5: Could regulatory changes impact the pricing or market for atorvastatin?
Yes. Approvals of combination therapies or biosimilars and changes in reimbursement policies could alter the market landscape.
References
[1] IQVIA, Market Insights Reports, 2022-2023.
[2] Pfizer Annual Reports, 2004-2010.
[3] FDA Database, Generic Drug Approvals, 2011–2022.
[4] Forte Research, Lipitor Market Analysis, 2022.
